-
Decoding tumor microenvironments through artificial tumor transcriptomes Cancer Cell (IF 38.585) Pub Date : 2022-08-08 Liqing Tian, Jinghui Zhang
In this issue of Cancer Cell, Zaitsev et al. (2022) present a machine-learning-based approach, trained from millions of artificial transcriptomes with admixed cell populations, for reconstructing tumor microenvironments (TMEs). The high accuracy of this approach, demonstrated through extensive validation, enables systematic investigation of TMEs in both research and clinical settings.
-
Metastasis Cancer Cell (IF 38.585) Pub Date : 2022-08-08 David Lyden, Cyrus M. Ghajar, Ana Luísa Correia, Julio A. Aguirre-Ghiso, Shang Cai, Maria Rescigno, Peiyuan Zhang, Guohong Hu, Sarah-Maria Fendt, Adrienne Boire, Ralph R. Weichselbaum, Rohan R. Katipally
Metastasis, the major cause of cancer death, represents one of the major challenges in oncology. Scientists are still trying to understand the biological basis underlying the dissemination and outgrowth of tumor cells, why these cells can remain dormant for years, how they become resistant to the immune system or cytotoxic effects of systemic therapy, and how they interact with their new microenvironment
-
Untangling the tumorigenic role of homotrimeric collagen I Cancer Cell (IF 38.585) Pub Date : 2022-08-08 Claus Jørgensen
Pancreatic ductal adenocarcinoma is characterized by a complex microenvironment. In this issue of Cancer Cell, Chen and colleagues define an oncogenic role of tumor-cell-produced collagen I homotrimers, wherein tumor development is promoted by integrin α3/β1-dependent activation of tumor cell signaling and modulation of tumor microbiome and immunity.
-
Precision medicine in AML: Function plus -omics is better than either alone Cancer Cell (IF 38.585) Pub Date : 2022-08-08 Anthony Letai
Morphology, immunophenotype, cytogenetics, and genomics have long dominated diagnostics in acute myelogenous leukemia (AML). In this issue of Cancer Cell, Bottomly et al. demonstrate that combining the above with transcriptomics and ex vivo drug testing of patient myeloblasts yields novel diagnostic and therapeutic insights with the potential for clinical translation.
-
Human and machine: Better at pathology together? Cancer Cell (IF 38.585) Pub Date : 2022-08-08 Alexander J. Lazar, Elizabeth G. Demicco
Meaningful integration of artificial intelligence (AI) will transform the application of “big data” for patient care, diagnosis, and research. In this issue of Cancer Cell, Chen et al. describe a transparent system to integrate histopathology and molecular data to predict outcomes and identify novel biomarkers in cancer.
-
Pan-cancer integrative histology-genomic analysis via multimodal deep learning Cancer Cell (IF 38.585) Pub Date : 2022-08-08 Richard J. Chen, Ming Y. Lu, Drew F.K. Williamson, Tiffany Y. Chen, Jana Lipkova, Zahra Noor, Muhammad Shaban, Maha Shady, Mane Williams, Bumjin Joo, Faisal Mahmood
-
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes Cancer Cell (IF 38.585) Pub Date : 2022-08-08 Aleksandr Zaitsev, Maksim Chelushkin, Daniiar Dyikanov, Ilya Cheremushkin, Boris Shpak, Krystle Nomie, Vladimir Zyrin, Ekaterina Nuzhdina, Yaroslav Lozinsky, Anastasia Zotova, Sandrine Degryse, Nikita Kotlov, Artur Baisangurov, Vladimir Shatsky, Daria Afenteva, Alexander Kuznetsov, Susan Raju Paul, Diane L. Davies, Alexander Bagaev
-
Dark genome, bright ideas: Recent approaches to harness transposable elements in immunotherapies Cancer Cell (IF 38.585) Pub Date : 2022-07-30 Ashley Reid Cahn, Nina Bhardwaj, Nicolas Vabret
Transposable elements (TEs), which make up almost half of the human genome, often display altered expression in cancers. Here, we review recent progress in elucidating the role of TEs as mediators of immune responses in cancer and discuss how novel therapeutic strategies can harness TE immunogenicity for cancer immunotherapy.
-
The aging lung microenvironment awakens melanoma metastases Cancer Cell (IF 38.585) Pub Date : 2022-07-21 Brandon M. Murphy, Christin E. Burd
In a recent publication in Nature, Fane et al. establish WNT5A as a central, age-sensitive regulator of the dormancy-to-reactivation axis of melanoma. They show that aged fibroblasts in the lungs suppress WNT5A signaling induced at the primary tumor site to awaken dormant melanoma cells and promote the outgrowth of metastases.
-
Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer Cancer Cell (IF 38.585) Pub Date : 2022-07-21 Yang Chen, Sujuan Yang, Jena Tavormina, Desiree Tampe, Michael Zeisberg, Huamin Wang, Krishnan K. Mahadevan, Chang-Jiun Wu, Hikaru Sugimoto, Chia-Chi Chang, Robert R. Jenq, Kathleen M. McAndrews, Raghu Kalluri
-
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia Cancer Cell (IF 38.585) Pub Date : 2022-07-21 Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson, Melissa Abel, Anupriya Agarwal, Sammantha Avaylon, Erik Benton, Aurora Blucher, Uma Borate, Theodore P. Braun, Jordana Brown, Jade Bryant, Russell Burke, Amy Carlos, Bill H. Chang, Jeffrey W. Tyner
-
Pan-cancer proteomic map of 949 human cell lines Cancer Cell (IF 38.585) Pub Date : 2022-07-14 Emanuel Gonçalves, Rebecca C. Poulos, Zhaoxiang Cai, Syd Barthorpe, Srikanth S. Manda, Natasha Lucas, Alexandra Beck, Daniel Bucio-Noble, Michael Dausmann, Caitlin Hall, Michael Hecker, Jennifer Koh, Howard Lightfoot, Sadia Mahboob, Iman Mali, James Morris, Laura Richardson, Akila J. Seneviratne, Roger R. Reddel
-
Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma Cancer Cell (IF 38.585) Pub Date : 2022-07-14 Anneloes van Krimpen, Vivian I.V. Gerretsen, Evalyn E.A.P. Mulder, Mandy van Gulijk, Thierry P.P. van den Bosch, Jan von der Thüsen, Dirk J. Grünhagen, Cornelis Verhoef, Dana Mustafa, Joachim G. Aerts, Ralph Stadhouders, Floris Dammeijer
Abstract not available
-
Node foretold: Cancer cells in lymph node rewire the immune system to enable further metastases Cancer Cell (IF 38.585) Pub Date : 2022-07-14 Hilda L. Chan, Xiang H.-F. Zhang
A Cell article reports that lymph node metastases can suppress the immune system, thereby promoting further cancer spread in mouse models; this is corroborated in patients as described in a letter in this issue of Cancer Cell. The lymph node thus actively generates a cancer-permissive environment and is an untapped target to manipulate the immune system.
-
Location of EGFR exon 20 insertions matters Cancer Cell (IF 38.585) Pub Date : 2022-07-11 Andrés Felipe Cardona, María González-Cao, Oscar Arrieta, Rafael Rosell
EGFR exon 20 insertions represent a subgroup of NSCLC patients posed with a therapy dilemma. In this issue of Cancer Cell, Elamin and colleagues demonstrate that only insertions localized in the near loop respond to poziotinib. Pharmacological inhibition of spindle assembly checkpoint components inhibits tumor growth in poziotinib-resistant exon 20 insertions.
-
New epigenetic regulators of T cell exhaustion Cancer Cell (IF 38.585) Pub Date : 2022-07-11 Haydn Kissick, Rafi Ahmed
In this issue of Cancer Cell, Belk et al. perform an in vitro CRISPR screen to identify genes that regulate CD8+ T cell exhaustion. They find several genes related to epigenetic modification and show that by eliminating Arid1a, CD8+ T cells retain proliferative and cytotoxic function in vivo, leading to better anti-tumor activity.
-
Immune pressure sculps tumor cells and trims high-quality mutations Cancer Cell (IF 38.585) Pub Date : 2022-07-11 Michal Bassani-Sternberg, Alexandre Harari
Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens’ immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.
-
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity Cancer Cell (IF 38.585) Pub Date : 2022-07-11 Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhang, Lauren A. Byers, Charles Lu, John V. Heymach
-
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer Cancer Cell (IF 38.585) Pub Date : 2022-07-01 Sidse Ehmsen, Anders Asmussen, Stefan S. Jeppesen, Anna Christine Nilsson, Amalie Kragh, Henrik Frederiksen, Henrik J. Ditzel
Abstract not available
-
Training the host organism to enhance anti-cancer immunity Cancer Cell (IF 38.585) Pub Date : 2022-06-23 Miriam Ferrer, Tobias Janowitz
In this issue of Cancer Cell, Kurz et al. demonstrate in an orthotopic pancreatic cancer model that low-intensity exercise improves tumor control and response to immunotherapy in an IL-15-dependent manner. Combination therapy, IL-15 super-agonist, anti-PD-1 antibody and chemotherapy, strongly reduces tumor growth. Therefore, the study opens rich translational avenues.
-
Sex and cancer immunotherapy: Current understanding and challenges Cancer Cell (IF 38.585) Pub Date : 2022-06-23 Laura Pala, Tommaso De Pas, Chiara Catania, Giuseppe Giaccone, Alberto Mantovani, Saverio Minucci, Giuseppe Viale, Richard D. Gelber, Fabio Conforti
Recent evidence highlights patients’ sex relevance in antitumor immune response through a complex interaction—among hormones, genes, behaviors, and the microbiome—that affects both innate and adaptive immune functions, as well as immune evasion mechanisms. These complex interactions ultimately influence the efficacy and toxicity of immune checkpoint inhibitors in solid tumors.
-
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence Cancer Cell (IF 38.585) Pub Date : 2022-06-23 Julia A. Belk, Winnie Yao, Nghi Ly, Katherine A. Freitas, Yan-Ting Chen, Quanming Shi, Alfredo M. Valencia, Eric Shifrut, Nupura Kale, Kathryn E. Yost, Connor V. Duffy, Bence Daniel, Madeline A. Hwee, Zhuang Miao, Alan Ashworth, Crystal L. Mackall, Alexander Marson, Julia Carnevale, Ansuman T. Satpathy
-
The local microenvironment matters in preclinical basic and translational studies of cancer immunology and immunotherapy Cancer Cell (IF 38.585) Pub Date : 2022-06-16 William W. Ho, Mikael J. Pittet, Dai Fukumura, Rakesh K. Jain
Abstract not available
-
Innate-like T cells: A promising asset in anti-cancer immunity Cancer Cell (IF 38.585) Pub Date : 2022-06-16 Martina Molgora, Marco Colonna
In Nature, Chou et al. identify a subset of innate-like αβ T cells with high cytotoxic potential that accumulate in tumors and elicit an anti-tumor response. Given their capacity to maintain an activation state without undergoing exhaustion, these innate-like T cells may represent effective therapeutic agents for cell-based approaches.
-
Cancer vaccines Cancer Cell (IF 38.585) Pub Date : 2022-06-13 John T. Schiller, Douglas R. Lowy, Ian H. Frazer, Olivera J. Finn, Eduardo Vilar, H. Kim Lyerly, Sacha Gnjatic, Neeha Zaidi, Patrick A. Ott, Vinod P. Balachandran, Pierre-Yves Dietrich, Denis Migliorini, Robert H. Vonderheide, Susan M. Domchek
Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.
-
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes Cancer Cell (IF 38.585) Pub Date : 2022-06-13 Carsten Denkert, Sibylle Loibl
The therapeutic landscape of breast cancer is becoming increasingly complex. In this issue of Cancer Cell, Wolf et al. present a breast cancer classification scheme that allows for better prediction of treatment response and can be continuously adapted to guide prioritization of new treatments.
-
Bacterial Darth Vader: May the force be with you Cancer Cell (IF 38.585) Pub Date : 2022-06-13 Kornelia Polyak
The microbiome has a major impact on tumor progression, yet the mechanisms are poorly defined. Fu et al. report in Cell that intracellular bacteria in a breast cancer model promote metastasis via reorganizing the cytoskeleton to enhance resistance to mechanical stress, thereby facilitating survival in the circulation during dissemination.
-
Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma Cancer Cell (IF 38.585) Pub Date : 2022-06-13 Vidhya M. Ravi, Paulina Will, Jan Kueckelhaus, Na Sun, Kevin Joseph, Henrike Salié, Lea Vollmer, Ugne Kuliesiute, Jasmin von Ehr, Jasim K. Benotmane, Nicolas Neidert, Marie Follo, Florian Scherer, Jonathan M. Goeldner, Simon P. Behringer, Pamela Franco, Mohammed Khiat, Junyi Zhang, Dieter Henrik Heiland
-
Resolving mutational signatures in cancer development Cancer Cell (IF 38.585) Pub Date : 2022-06-09 Tianyuan Liu, Yuan Lin, Chen Wu
In a recent Science study, an advanced mutational signature analysis was performed on an unprecedentedly large set of cancer whole-genome sequences across multiple organs. This work introduces a computational framework to identify common and rare mutational signatures and provides insights into their biological interpretation.
-
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer Cancer Cell (IF 38.585) Pub Date : 2022-06-02 Emma Kurz, Carolina Alcantara Hirsch, Tanner Dalton, Sorin Alberto Shadaloey, Alireza Khodadadi-Jamayran, George Miller, Sumedha Pareek, Hajar Rajaei, Chirayu Mohindroo, Seyda Baydogan, An Ngo-Huang, Nathan Parker, Matthew H.G. Katz, Maria Petzel, Emily Vucic, Florencia McAllister, Keri Schadler, Rafael Winograd, Dafna Bar-Sagi
-
Combination immune checkpoint blockade in advanced untreated gastroesophageal adenocarcinoma: Seeking biomarkers for durable benefit Cancer Cell (IF 38.585) Pub Date : 2022-06-02 Elisa Fontana, Elizabeth C. Smyth
The CheckMate 649 trial, recently published in Nature, established chemotherapy plus nivolumab as a standard in advanced, treatment-naive gastroesophageal adenocarcinoma, with best results seen in patients with high PD-L1 expression and microsatellite unstable tumors. In contrast, nivolumab plus ipilimumab, compared with chemotherapy, showed early progression and no overall survival benefit.
-
When immunotherapy meets surgery in non-small cell lung cancer Cancer Cell (IF 38.585) Pub Date : 2022-06-02 Roy S. Herbst, Meina Wang, Lieping Chen
The results of the most recent Checkmate-816 trial in The New England Journal of Medicine using combination neoadjuvant immunotherapy with platinum-based chemotherapy in resectable non-small cell lung cancer demonstrate the effectiveness of neoadjuvant immunotherapy and provide further support that biology and personalized therapy represent the foundation of lung cancer treatment.
-
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses Cancer Cell (IF 38.585) Pub Date : 2022-05-30 Olga Lyudovyk, Justin Y. Kim, David Qualls, Madeline A. Hwee, Ya-Hui Lin, Sawsan R. Boutemine, Yuval Elhanati, Alexander Solovyov, Melanie Douglas, Eunise Chen, N. Esther Babady, Lakshmi Ramanathan, Pallavi Vedantam, Chaitanya Bandlamudi, Sigrid Gouma, Philip Wong, Scott E. Hensley, Benjamin Greenbaum, Santosha A. Vardhana
-
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies Cancer Cell (IF 38.585) Pub Date : 2022-05-26 Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark J. Magbanua, Rosalyn Sayaman, Nicholas O’Grady, Amrita Basu, Amy Delson, Jean Philippe Coppé, Ruixiao Lu, Jerome Braun, Smita M. Asare, Laura Sit, Laura J. van 't Veer
-
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer Cancer Cell (IF 38.585) Pub Date : 2022-05-26 Kelly Kersten, Kenneth H. Hu, Alexis J. Combes, Bushra Samad, Tory Harwin, Arja Ray, Arjun Arkal Rao, En Cai, Kyle Marchuk, Jordan Artichoker, Tristan Courau, Quanming Shi, Julia Belk, Ansuman T. Satpathy, Matthew F. Krummel
-
Tracing back to one of the origins of immune evasion in pancreatic cancer Cancer Cell (IF 38.585) Pub Date : 2022-05-26 Joaquín Araos Henríquez, Giulia Biffi
In this issue of Cancer Cell, Huang et al. identify the origin and function of a subset of pancreatic cancer-associated fibroblasts. This work further highlights the power of lineage-tracing models for dissecting the tumor microenvironment in pancreatic cancer and provides new knowledge toward the development of novel therapeutic strategies.
-
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy Cancer Cell (IF 38.585) Pub Date : 2022-05-19 Haixia Long, Qingzhu Jia, Liuyang Wang, Wenfeng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Zheng Jin, Jiani Huang, Li Zhou, Chunyan Hu, Xinxin Wang, Jin Zhang, Yujie Ba, Yujie Gong, Xianghua Zeng, Dong Zeng, Xingxing Su, Bo Zhu
-
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells Cancer Cell (IF 38.585) Pub Date : 2022-05-19 Jessica K. Mandula, Paulo C. Rodriguez
In this issue of Cancer Cell, Long et al. demonstrate that tumors can reprogram erythroid progenitors into myeloid-erythroid cells that promote immunosuppression. Erythroid-differentiated myeloid cells (EDMCs) expand in cancer-bearing individuals, resemble the functionality of myeloid-derived suppressor cells (MDSCs), and correlate with poor response to immune-checkpoint inhibitors (ICIs) and tumor-related
-
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies Cancer Cell (IF 38.585) Pub Date : 2022-05-16 Robert Stuver, Gunjan L. Shah, Neha S. Korde, Lindsey E. Roeker, Anthony R. Mato, Connie L. Batlevi, David J. Chung, Sital Doddi, Lorenzo Falchi, Boglarka Gyurkocza, Audrey Hamilton, Ya-Hui Lin, Ann A. Jakubowski, Erel Joffe, Heather L. Landau, Richard J. Lin, Sham Mailankody, M. Lia Palomba, Santosha A. Vardhana
Abstract not available
-
Translational research: A patient-centered approach to bridge the valley of death Cancer Cell (IF 38.585) Pub Date : 2022-05-12 Anish Thomas, Parth Desai, Nobuyuki Takahashi
Animal models have evolved to be a key component of translational research of cancer, and they are now extensively used to test drug candidates, predict drug responses, and essentially drive discovery of cancer biology. However, the model-centric approach has not yielded the expected abundance of treatment advances. We propose that the focus of translational research needs to shift from animal models
-
Fast track to personalized TCR T cell therapies Cancer Cell (IF 38.585) Pub Date : 2022-05-09 Pierre L. Levy, Alena Gros
In this issue of Cancer Cell, Hanada et al. leverage single-cell multi-omics of lung cancer resident lymphocytes to identify phenotypic and transcriptomic signatures differentially expressed by neoantigen-reactive clonotypes. These findings could substantially expedite the selection of neoantigen-specific T cell receptors (TCRs) for individualized T cell therapies.
-
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy Cancer Cell (IF 38.585) Pub Date : 2022-05-09 Julie Delyon, Celeste Lebbe
Increasing the efficacy of immune checkpoint blockade therapy while mitigating toxicity is one of the major challenges in oncology research. In this issue of Cancer Cell, Hailemichael et al. provide a strong rationale for the combination of IL-6 blockade and dual inhibition of CTLA-4 and PD-1 to overcome this issue.
-
Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer Cancer Cell (IF 38.585) Pub Date : 2022-05-09 Takemasa Tsuji, Junko Matsuzaki, Kunle Odunsi
In this issue of Cancer Cell, Anadon et al. perform a multi-omics analysis of ovarian tumor infiltrating tissue-resident memory T (TRM) cells at the single-cell level that supports a differentiation model from CD103−TCF1+ re-circulating T-cell precursors driven by tumor antigen recognition. CD103+ TRM cells play a dominant anti-tumor role in ovarian cancer.
-
Boosting anticancer immunotherapy through androgen receptor blockade Cancer Cell (IF 38.585) Pub Date : 2022-05-09 Laura Pala, Tommaso De Pas, Fabio Conforti
Immune checkpoint inhibitors (ICIs) have limited activity in patients with castration-resistant prostate cancer (CRPC). A Nature article demonstrates that androgen receptor (AR) negatively modulates CD8+ T cell-driven antitumor immune response and that androgen-axis blockade is a promising therapeutic strategy to improve ICI activity in CRPC.
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity Cancer Cell (IF 38.585) Pub Date : 2022-05-09 Yared Hailemichael, Daniel H. Johnson, Noha Abdel-Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher, Cara Haymaker, Khalida Wani, Chantal Saberian, Dai Ogata, Sang T. Kim, Roza Nurieva, Alexander J. Lazar, Hamzah Abu-Sbeih, Faisal Fa'ak, Antony Mathew, Yinghong Wang, Adewunmi Falohun, Adi Diab
-
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes Cancer Cell (IF 38.585) Pub Date : 2022-05-09 Abhinav Jaiswal, Akanksha Verma, Ruth Dannenfelser, Marit Melssen, Itay Tirosh, Benjamin Izar, Tae-Gyun Kim, Christopher J. Nirschl, K. Sanjana P. Devi, Walter C. Olson, Craig L. Slingluff, Victor H. Engelhard, Levi Garraway, Aviv Regev, Kira Minkis, Charles H. Yoon, Olga Troyanskaya, Olivier Elemento, Niroshana Anandasabapathy
-
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma Cancer Cell (IF 38.585) Pub Date : 2022-05-08 Julius C. Enssle, Julia Campe, Sarah Büchel, Alina Moter, Frederic See, Katharina Grießbaum, Michael A. Rieger, Sebastian Wolf, Olivier Ballo, Björn Steffen, Hubert Serve, Holger F. Rabenau, Marek Widera, Melanie Bremm, Sabine Huenecke, Sandra Ciesek, Ivana von Metzler, Evelyn Ullrich
Abstract not available
-
COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia Cancer Cell (IF 38.585) Pub Date : 2022-05-06 Helen Parry, Rachel Bruton, Thomas Roberts, Graham McIlroy, Sarah Damery, Panagiota Sylla, Alexander C. Dowell, Gokhan Tut, Tara Lancaster, David Bone, Brian Willett, Nicola Logan, Sam Scott, Sam Hulme, Azar Jadir, Umayr Amin, Sam Nicol, Christine Stephens, Paul Moss
Abstract not available
-
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer Cancer Cell (IF 38.585) Pub Date : 2022-05-05 Huocong Huang, Zhaoning Wang, Yuqing Zhang, Rachana N. Pradhan, Debolina Ganguly, Raghav Chandra, Gilbert Murimwa, Steven Wright, Xiaowu Gu, Ravikanth Maddipati, Sören Müller, Shannon J. Turley, Rolf A. Brekken
-
The translational challenges of precision oncology Cancer Cell (IF 38.585) Pub Date : 2022-04-28 Oriol Pich, Chris Bailey, Thomas B.K. Watkins, Simone Zaccaria, Mariam Jamal-Hanjani, Charles Swanton
The translational challenges in the field of precision oncology are in part related to the biological complexity and diversity of this disease. Technological advances in genomics have facilitated large sequencing efforts and discoveries that have further supported this notion. In this review, we reflect on the impact of these discoveries on our understanding of several concepts: cancer initiation,
-
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition Cancer Cell (IF 38.585) Pub Date : 2022-04-28 Justin T. Low, Vidyalakshmi Chandramohan, Michelle L. Bowie, Michael C. Brown, Matthew S. Waitkus, Aaron Briley, Kevin Stevenson, Rebecca Fuller, Zachary J. Reitman, Andrea M. Muscat, Seethalakshmi Hariharan, Janell Hostettler, Sarah Danehower, Ali Baker, Mustafa Khasraw, Nicholas C. Wong, Simon Gregory, Smita K. Nair, David M. Ashley
Abstract not available
-
Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors Cancer Cell (IF 38.585) Pub Date : 2022-04-28 Leonid Cherkassky, Zhaohua Hou, Alfredo Amador-Molina, Prasad S. Adusumilli
The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.
-
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study Cancer Cell (IF 38.585) Pub Date : 2022-04-26 Martin Schönlein, Victoria Wrage, Susanne Ghandili, Sibylle C. Mellinghoff, Thomas Theo Brehm, Lisa B. Leypoldt, Nils Utz, Roland M. Schrader, Winfried Alsdorf, Niklas Börschel, Lara Bußmann, Martin Schönrock, Dorothea Perlick, Gerhard Schön, Karl Verpoort, Marc Lütgehetmann, Julian Schulze zur Wiesch, Katja C. Weisel, Marianne Sinn
Abstract not available
-
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia Cancer Cell (IF 38.585) Pub Date : 2022-04-21 Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca Larson, Bryan D. Choi, Amanda A. Bouffard, Kathleen Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Nora Horick, Matthew J. Frigault, Marcela V. Maus
-
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers Cancer Cell (IF 38.585) Pub Date : 2022-04-21 Ken-ichi Hanada, Chihao Zhao, Raul Gil-Hoyos, Jared J. Gartner, Christopher Chow-Parmer, Frank J. Lowery, Sri Krishna, Todd D. Prickett, Scott Kivitz, Maria R. Parkhurst, Nathan Wong, Zachary Rae, Michael C. Kelly, Stephanie L. Goff, Paul F. Robbins, Steven A. Rosenberg, James C. Yang
-
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge Cancer Cell (IF 38.585) Pub Date : 2022-04-21 Yotam Bronstein, Roi Gat, Shai Levi, Yael C. Cohen, Efrat Luttwak, Noam Benyamini, Tamir Shragai, Roy Vitkon, Miriam Neaman, Nili Eilaty, Mor Levi, Svetlana Trestman, Chava Perry, Yair Herishanu, Irit Avivi
Abstract not available
-
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer Cancer Cell (IF 38.585) Pub Date : 2022-04-20 Philip C. Mack, Jorge E. Gomez, Ananda M. Rodilla, Juan Manuel Carreño, Chih-Yuan Hsu, Christian Rolfo, Noy Meshulami, Amy Moore, Rachel I. Brody, Jennifer C. King, Jacquelyn Treatman, Sooyun Lee, Ariel Raskin, Komal Srivastava, Charles R. Gleason, Diego de Miguel-Perez
Abstract not available
-
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells Cancer Cell (IF 38.585) Pub Date : 2022-04-14 Carmen M. Anadon, Xiaoqing Yu, Kay Hänggi, Subir Biswas, Ricardo A. Chaurio, Alexandra Martin, Kyle K. Payne, Gunjan Mandal, Patrick Innamarato, Carly M. Harro, Jessica A. Mine, Kimberly B. Sprenger, Carla Cortina, John J. Powers, Tara Lee Costich, Bradford A. Perez, Chandler D. Gatenbee, Sandhya Prabhakaran, Jose R. Conejo-Garcia
-
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron Cancer Cell (IF 38.585) Pub Date : 2022-04-12 Maximilian J. Mair, Manfred Mitterer, Pia Gattinger, Julia M. Berger, Wolfgang Trutschnig, Arne C. Bathke, Margaretha Gansterer, Anna S. Berghoff, Severin Laengle, Lynn Gottmann, Thomas Buratti, Helmuth Haslacher, Wolfgang W. Lamm, Markus Raderer, Selma Tobudic, Thorsten Fuereder, Rudolf Valenta, Dominic Fong, Matthias Preusser
Abstract not available
-
Tracking down tumor-specific T cells Cancer Cell (IF 38.585) Pub Date : 2022-04-11 James Reading, Kane Foster, Kroopa Joshi, Benny Chain
Two papers published in this edition of Cancer Cell (Zheng et al., 2022 and Veatch et al., 2022) provide an elegant illustration of how single-cell sequencing can be used to define a molecular phenotype which identifies tumor-specific T cells.